The flow cytometry-based assay measures the expression of the protein FcyR11a as a biomarker for cardiovascular risk.
The UK-based firm is developing its initial panel tests for Gram-negative bacteria with tests for Gram-positive bacteria and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback